TNGX Stock Overview
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer.
Tango Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.97|
|52 Week High||US$18.84|
|52 Week Low||US$3.71|
|1 Month Change||6.20%|
|3 Month Change||0%|
|1 Year Change||-50.25%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-51.42%|
Recent News & Updates
Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M
Tango Therapeutics press release (NASDAQ:TNGX): Q2 GAAP EPS of -$0.28 beats by $0.03. Revenue of $5.78M (-68.2% Y/Y) beats by $0.12M.
We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|TNGX||US Biotechs||US Market|
Return vs Industry: TNGX underperformed the US Biotechs industry which returned -25.9% over the past year.
Return vs Market: TNGX underperformed the US Market which returned -13.5% over the past year.
|TNGX Average Weekly Movement||13.9%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: TNGX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: TNGX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers.
Tango Therapeutics, Inc. Fundamentals Summary
|TNGX fundamental statistics|
Is TNGX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TNGX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.81|
|Net Profit Margin||-195.91%|
How did TNGX perform over the long term?See historical performance and comparison